The First New Drug Class in Over a Decade

The FDA approved Jascayd (nerandomilast) tablets for progressive pulmonary fibrosis in adults. September 2026. First and only preferential phosphodiesterase 4B inhibitor with immunomodulatory and antifibrotic effects approved for this indication.

First new antifibrotic drug class in over a decade.

I have pulmonary fibrosis. Diagnosed July 2024: interstitial lung disease, bronchiectasis, COPD, CRPD, asthma. Prognosis was 6 months to 2 years. That was July 2024. I'm still here, 26 months later.

So when a new drug class clears FDA approval, I pay attention.

WHAT IT DOES

Nerandomilast is a PDE4B inhibitor. Phosphodiesterase 4B sits inside immune cells and inflammatory cells – inhibiting it reduces inflammation and slows fibrotic scarring in lung tissue.

The pivotal Phase III FIBRONEER-ILD trial demonstrated nerandomilast effectively slowed lung function decline in progressive pulmonary fibrosis, with similar permanent discontinuation rates to placebo. That second part matters: the drug works without making people quit because of side effects.

UK Medicines and Healthcare products Regulatory Agency approved Jascayd for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis on July 8, 2026. Regulatory submissions under review in the EU, Japan, and other countries. Further approvals anticipated in 2026 (Boehringer Ingelheim, 2026).

Inhaled treprostinil also showed positive Phase III results. Two parallel studies – TETON-1 and TETON-2 – demonstrated significantly less one-year forced vital capacity decline versus placebo in idiopathic pulmonary fibrosis patients, and fewer clinical-worsening events over 52 weeks. Published in The New England Journal of Medicine March 11, 2026, presented at the 2025 European Respiratory Society Congress.

THE CONTEXT

Treatment options for pulmonary fibrosis have been limited. Pirfenidone and nintedanib were the existing antifibrotics. Both slow disease progression. Neither reverses scarring.

Corticosteroids were standard for sarcoidosis-associated pulmonary fibrosis, along with second-line agents like methotrexate and azathioprine, and third-line TNF inhibitors. Research shifted focus from classical Th1 cells to Th17.1 cells – now recognized as the primary source of interferon-gamma in the pulmonary microenvironment, closely associated with disease chronicity and glucocorticoid resistance. Treatment paradigms changed: shift away from excessive corticosteroid use toward steroid-sparing agents with less cumulative toxicity (Frontiers in Medicine, February 2026: https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2026.1754491/full).

Nintedanib reduced the adjusted rate of forced vital capacity decline by 107.0 mL per year versus placebo over 52 weeks. A pirfenidone trial is ongoing for progressive fibrotic sarcoidosis.

Nerandomilast offers a different mechanism: immunomodulation through PDE4B inhibition, not just antifibrotic action.

WHAT THIS MEANS

For someone with this diagnosis, a new drug class is not hope. It's OPTIONS.

Hope is what you sell to people who don't read the studies. Options are what you get when a compound clears Phase III trials and regulatory review in multiple countries.

The original prognosis gave me 6 months to 2 years. I hit 26 months in September 2026. Every month past that window is borrowed time, and borrowed time runs on lung function I don't get back.

FVC – forced vital capacity – is the measure. How much air you can forcibly exhale after taking the deepest breath possible. Mine declines. Slowly. That decline is the clock.

Slowing the decline doesn't reverse scarring. But it extends the runway. More time before supplemental oxygen becomes continuous. More time before a portable concentrator becomes permanent equipment. More time before stairs become something I plan around instead of just take.

Nerandomilast slowed FVC decline in the trial population. Inhaled treprostinil did the same in two separate studies. These are not miracle cures. They are incremental gains measured in milliliters per year.

Milliliters per year matter when the alternative is losing function on a schedule you can't negotiate.

The FDA approval means U.S. prescribers can write for it. UK MHRA approval means it's available there. EU and Japan reviews in progress mean it's spreading.

That's the difference between one option and multiple options. Between "take pirfenidone or nintedanib" and "take pirfenidone, nintedanib, nerandomilast, or inhaled treprostinil, or some combination we trial for your specific presentation."

THE VERDICT

First new antifibrotic drug class in over a decade means the research pipeline didn't dry up. Means pharmaceutical companies see enough of a patient population – and enough of a revenue model – to fund Phase III trials. Means regulatory agencies are clearing drugs that work by different mechanisms.

For patients, that's not inspiration. It's arithmetic. More mechanisms mean more chances one of them works for your particular scarring pattern. More approvals mean more access points when insurance denies the first option.

I'll ask my pulmonologist about nerandomilast. He'll check the contraindications against my other medications, run the numbers on my current FVC trend, and either write the script or explain why not.

That's how it works when you're 26 months past a 6-to-24-month prognosis and a new drug class clears FDA approval.

You don't hope. You ask.